Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Semaglutide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Verdict
Mostly mechanism / observational
Top outcomes
250-500mg combined EPA+DHA daily for general health; up to 1000mg+ DHA for higher omega-3 status or triglyceride goals
with-meals
Algal DHA oil (or EPA+DHA oil)
Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.
any
Subcutaneous once-weekly injection (Ozempic / Wegovy)
4-12 weeks
Weeks at adequate dose
Long term
Weeks to months
Months (titrated over 16-20 weeks)
Months to years
Especially during dose escalation
Algal-oil capsules and cooked salmon: nutritionally equivalent sources of docosahexaenoic acid.
J Am Diet Assoc (2008) · Rct · n=32 healthy adults
Both sources raised plasma phospholipid DHA ~80% and erythrocyte DHA ~25%
Bioequivalence of docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food.
Lipids (2007) · Rct · n=60 (12 per group)
Algal DHA capsules and DHA-fortified food were bioequivalent for DHA delivery
High-fat meals rich in EPA plus DHA compared with DHA only have differential effects on postprandial lipemia and plasma 8-isoprostane F2alpha concentrations relative to a control high-oleic acid meal.
Am J Clin Nutr (2014) · Crossover · n=16 men
Fish oil (EPA+DHA) modestly reduced the postprandial triacylglycerol rise versus control
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).
N Engl J Med (2021) · Rct · n=1961
Double-blind RCT in 1,961 adults with obesity/overweight WITHOUT diabetes, randomized 2:1 to subcutaneous semaglutide 2.4 mg/week or placebo plus lifestyle for 68 weeks
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).
N Engl J Med (2023) · Rct · n=17604
Large cardiovascular-outcomes RCT: 17,604 patients with preexisting cardiovascular disease and overweight/obesity but WITHOUT diabetes
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).
N Engl J Med (2016) · Rct · n=3297
Pre-approval cardiovascular-safety RCT in 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide (0.5/1.0 mg/week) vs placebo for 104 weeks
Semaglutide has a higher evidence score (8.5/10 vs 5.5/10) and wins in 2 of 3 categories.
No known interactions between Algae Oil and Semaglutide have been documented in our database. However, always consult a healthcare provider before combining supplements.